Medium-Term Outcomes of the Different Antithrombotic Regimens After Transcatheter Aortic Valve Implantation
Copyright © 2023 Elsevier Inc. All rights reserved..
Bioprosthetic valve thrombosis is associated with accelerated bioprosthesis degeneration and valve re-replacement. Whether 3-month warfarin use after transcatheter aortic valve implantation (TAVI) protects against such consequences is unknown. We aimed to investigate if 3-month warfarin treatment after TAVI is associated with better outcomes than dual antiplatelet therapy (DAPT) and single antiplatelet therapy (SAPT) at medium-term follow-up. Adults who underwent TAVI were identified retrospectively (n = 1,501) and classified into warfarin, DAPT, and SAPT groups based on antithrombotic regimen received. Patients with atrial fibrillation were excluded. Outcomes and valve hemodynamics were compared between the groups. Annualized change from baseline in mean gradients and effective orifice area at last follow-up echocardiography was calculated. Overall, 844 patients were included (mean age: 80 ± 9 years, 43% women; 633 receiving warfarin, 164 DAPT, and 47 SAPT). Median time to follow-up was 2.5 (interquartile range 1.2 to 3.9) years. There were no differences in the adjusted outcome end points of ischemic stroke, death, valve re-replacement/intervention, structural valve degeneration, or their composite end point at follow-up. Annualized change in aortic valve area was significantly higher in DAPT (-0.11 [0.19] cm2/year) than warfarin (-0.06 [0.25] cm2/y, p = 0.03), but annualized change in mean gradients was not different (p >0.05). In conclusion, antithrombotic regimen, including warfarin, after TAVI was associated with marginally lower decrease in aortic valve area but no difference in medium-term clinical outcomes compared with DAPT and SAPT.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:198 |
|---|---|
| Enthalten in: |
The American journal of cardiology - 198(2023) vom: 01. Juli, Seite 113-123 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Naser, Jwan A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
5Q7ZVV76EI |
|---|
| Anmerkungen: |
Date Completed 13.06.2023 Date Revised 23.06.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.amjcard.2023.04.014 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM357048636 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM357048636 | ||
| 003 | DE-627 | ||
| 005 | 20231226071743.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.amjcard.2023.04.014 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1190.xml |
| 035 | |a (DE-627)NLM357048636 | ||
| 035 | |a (NLM)37202327 | ||
| 035 | |a (PII)S0002-9149(23)00214-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Naser, Jwan A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Medium-Term Outcomes of the Different Antithrombotic Regimens After Transcatheter Aortic Valve Implantation |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.06.2023 | ||
| 500 | |a Date Revised 23.06.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier Inc. All rights reserved. | ||
| 520 | |a Bioprosthetic valve thrombosis is associated with accelerated bioprosthesis degeneration and valve re-replacement. Whether 3-month warfarin use after transcatheter aortic valve implantation (TAVI) protects against such consequences is unknown. We aimed to investigate if 3-month warfarin treatment after TAVI is associated with better outcomes than dual antiplatelet therapy (DAPT) and single antiplatelet therapy (SAPT) at medium-term follow-up. Adults who underwent TAVI were identified retrospectively (n = 1,501) and classified into warfarin, DAPT, and SAPT groups based on antithrombotic regimen received. Patients with atrial fibrillation were excluded. Outcomes and valve hemodynamics were compared between the groups. Annualized change from baseline in mean gradients and effective orifice area at last follow-up echocardiography was calculated. Overall, 844 patients were included (mean age: 80 ± 9 years, 43% women; 633 receiving warfarin, 164 DAPT, and 47 SAPT). Median time to follow-up was 2.5 (interquartile range 1.2 to 3.9) years. There were no differences in the adjusted outcome end points of ischemic stroke, death, valve re-replacement/intervention, structural valve degeneration, or their composite end point at follow-up. Annualized change in aortic valve area was significantly higher in DAPT (-0.11 [0.19] cm2/year) than warfarin (-0.06 [0.25] cm2/y, p = 0.03), but annualized change in mean gradients was not different (p >0.05). In conclusion, antithrombotic regimen, including warfarin, after TAVI was associated with marginally lower decrease in aortic valve area but no difference in medium-term clinical outcomes compared with DAPT and SAPT | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Platelet Aggregation Inhibitors |2 NLM | |
| 650 | 7 | |a Fibrinolytic Agents |2 NLM | |
| 650 | 7 | |a Warfarin |2 NLM | |
| 650 | 7 | |a 5Q7ZVV76EI |2 NLM | |
| 700 | 1 | |a Kucuk, Hilal Olgun |e verfasserin |4 aut | |
| 700 | 1 | |a Gochanour, Benjamin R |e verfasserin |4 aut | |
| 700 | 1 | |a Scott, Christopher G |e verfasserin |4 aut | |
| 700 | 1 | |a Kennedy, Austin M |e verfasserin |4 aut | |
| 700 | 1 | |a Luis, S Allen |e verfasserin |4 aut | |
| 700 | 1 | |a Pislaru, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Greason, Kevin L |e verfasserin |4 aut | |
| 700 | 1 | |a Crestanello, Juan A |e verfasserin |4 aut | |
| 700 | 1 | |a Gulati, Rajiv |e verfasserin |4 aut | |
| 700 | 1 | |a Eleid, Mackram F |e verfasserin |4 aut | |
| 700 | 1 | |a Nkomo, Vuyisile T |e verfasserin |4 aut | |
| 700 | 1 | |a Pislaru, Sorin V |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The American journal of cardiology |d 1958 |g 198(2023) vom: 01. Juli, Seite 113-123 |w (DE-627)NLM000025364 |x 1879-1913 |7 nnns |
| 773 | 1 | 8 | |g volume:198 |g year:2023 |g day:01 |g month:07 |g pages:113-123 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.amjcard.2023.04.014 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 198 |j 2023 |b 01 |c 07 |h 113-123 | ||